AngioDynamics (NASDAQ:ANGO) Sets New 52-Week High – What’s Next?

AngioDynamics, Inc. (NASDAQ:ANGO)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $16.29 and last traded at $16.00, with a volume of 7297 shares trading hands. The stock had previously closed at $16.13.

Wall Street Analyst Weigh In

Several research firms have recently commented on ANGO. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. HC Wainwright raised their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Finally, Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and an average price target of $19.50.

AngioDynamics Price Performance

The company’s 50 day moving average price is $14.53 and its 200 day moving average price is $12.35. The firm has a market cap of $645.61 million, a PE ratio of -17.95 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Sell-side analysts expect that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in AngioDynamics in the 2nd quarter valued at about $49,480,000. Millennium Management LLC boosted its stake in shares of AngioDynamics by 28.1% in the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the period. Kotler Kevin acquired a new position in shares of AngioDynamics during the fourth quarter worth about $21,997,000. Armistice Capital LLC increased its stake in shares of AngioDynamics by 3.9% during the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after buying an additional 64,000 shares during the period. Finally, Weber Capital Management LLC ADV purchased a new stake in shares of AngioDynamics during the second quarter worth approximately $17,649,392. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.